Speaker

Bastiaan van der Baan | Chief Executive Officer, Lixte Biotechnology Holdings

Bas van der Baan is biotech executive, business leader and strong team builder who identifies and empowers team members with the required skill sets to bring new insights and innovations in biology to patients. Over 20 years experience in the biotechnology industry. Played a key role in financing activities with over $200 million raised. He co-founded Agendia Inc (US), developed, and sold a liquid biopsy molecular diagnostic company to market leader. Bas is currently Chief Executive Officer at Lixte (NASDAQ: LIXT), is a venture partner at XGEN venture fund and holds a board position at Tethis (Italy). He graduated from Wageningen University with a Masters degree in Molecular Sciences.

About Lixte Biotechnology Holdings

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors. The Company’s innovative approach enhances the efficacy of both chemotherapy and immunotherapy, potentially providing new treatment options for patients. At the core of the Company’s therapy is LB-100, the Company’s proprietary compound that acts as an inhibitor of the PP2A phosphatase with a favorable toxicity profile. LB-100 promotes the production of neoantigens and cytokines, boosts T-cell proliferation, and disrupts the DNA repair mechanisms of cancer cells, potentially improving treatment outcomes. The Company is conducting multiple clinical trials for solid tumors with unmet medical needs.

Powered by:
Hyphen Projects

Let's connect:

Book a ticket

FAQ
Contact Us
Privacy Policy
Terms & Conditions
Chamber of Commerce: 32110979
VAT no: NL8184.34.491.B01

Keep me informed Download our event app

© Copyright 2023 by Hyphen Projects